Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 2
1995 3
1998 9
1999 1
2000 4
2001 6
2002 6
2003 4
2004 1
2005 7
2006 2
2007 11
2008 7
2009 8
2010 9
2011 1
2012 6
2013 7
2014 3
2015 4
2016 6
2017 13
2018 6
2019 6
2020 6
Text availability
Article attribute
Article type
Publication date

Search Results

130 results
Results by year
Filters applied: . Clear all
Page 1
Anti-CTLA-4 therapy for malignant mesothelioma.
Guazzelli A, Bakker E, Krstic-Demonacos M, Lisanti MP, Sotgia F, Mutti L. Guazzelli A, et al. Among authors: Mutti L. Immunotherapy. 2017 Mar;9(3):273-280. doi: 10.2217/imt-2016-0123. Immunotherapy. 2017. PMID: 28231719 Review.
Immunotherapy advances for mesothelioma treatment.
Bakker E, Guazzelli A, Ashtiani F, Demonacos C, Krstic-Demonacos M, Mutti L. Bakker E, et al. Among authors: Mutti L. Expert Rev Anticancer Ther. 2017 Sep;17(9):799-814. doi: 10.1080/14737140.2017.1358091. Epub 2017 Jul 31. Expert Rev Anticancer Ther. 2017. PMID: 28724330 Review.
Repurposing atovaquone: targeting mitochondrial complex III and OXPHOS to eradicate cancer stem cells.
Fiorillo M, Lamb R, Tanowitz HB, Mutti L, Krstic-Demonacos M, Cappello AR, Martinez-Outschoorn UE, Sotgia F, Lisanti MP. Fiorillo M, et al. Among authors: Mutti L. Oncotarget. 2016 Jun 7;7(23):34084-99. doi: 10.18632/oncotarget.9122. Oncotarget. 2016. PMID: 27136895 Free PMC article.
Targeting hypoxic response for cancer therapy.
Paolicchi E, Gemignani F, Krstic-Demonacos M, Dedhar S, Mutti L, Landi S. Paolicchi E, et al. Among authors: Mutti L. Oncotarget. 2016 Mar 22;7(12):13464-78. doi: 10.18632/oncotarget.7229. Oncotarget. 2016. PMID: 26859576 Free PMC article. Review.
Switching off malignant mesothelioma: exploiting the hypoxic microenvironment.
Nabavi N, Bennewith KL, Churg A, Wang Y, Collins CC, Mutti L. Nabavi N, et al. Among authors: Mutti L. Genes Cancer. 2016 Nov;7(11-12):340-354. doi: 10.18632/genesandcancer.124. Genes Cancer. 2016. PMID: 28191281 Free PMC article. Review.
Tremelimumab for the treatment of malignant mesothelioma.
Guazzelli A, Hussain M, Krstic-Demonacos M, Mutti L. Guazzelli A, et al. Among authors: Mutti L. Expert Opin Biol Ther. 2015;15(12):1819-29. doi: 10.1517/14712598.2015.1116515. Expert Opin Biol Ther. 2015. PMID: 26560442 Review.
Scientific Advances and New Frontiers in Mesothelioma Therapeutics.
Mutti L, Peikert T, Robinson BWS, Scherpereel A, Tsao AS, de Perrot M, Woodard GA, Jablons DM, Wiens J, Hirsch FR, Yang H, Carbone M, Thomas A, Hassan R. Mutti L, et al. J Thorac Oncol. 2018 Sep;13(9):1269-1283. doi: 10.1016/j.jtho.2018.06.011. J Thorac Oncol. 2018. PMID: 29966799 Free PMC article. Review.
Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma.
Guazzelli A, Bakker E, Tian K, Demonacos C, Krstic-Demonacos M, Mutti L. Guazzelli A, et al. Among authors: Mutti L. Expert Opin Investig Drugs. 2017 Aug;26(8):933-944. doi: 10.1080/13543784.2017.1351545. Epub 2017 Jul 12. Expert Opin Investig Drugs. 2017. PMID: 28679291 Review.
The role of microenvironment and immunity in drug response in leukemia.
Bakker E, Qattan M, Mutti L, Demonacos C, Krstic-Demonacos M. Bakker E, et al. Among authors: Mutti L. Biochim Biophys Acta. 2016 Mar;1863(3):414-426. doi: 10.1016/j.bbamcr.2015.08.003. Epub 2015 Aug 6. Biochim Biophys Acta. 2016. PMID: 26255027 Free article. Review.
Surgery for malignant pleural mesothelioma: an international guidelines review.
Ricciardi S, Cardillo G, Zirafa CC, Carleo F, Facciolo F, Fontanini G, Mutti L, Melfi F. Ricciardi S, et al. Among authors: Mutti L. J Thorac Dis. 2018 Jan;10(Suppl 2):S285-S292. doi: 10.21037/jtd.2017.10.16. J Thorac Dis. 2018. PMID: 29507797 Free PMC article. Review.
130 results
Jump to page